64 Participants Needed

GP-2250 + Gemcitabine for Pancreatic Cancer

Recruiting at 8 trial locations
JC
TM
KM
Overseen ByKathryn M Martin, PharmD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Geistlich Pharma AG
Must be taking: Gemcitabine
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug, GP-2250, combined with gemcitabine for patients with advanced pancreatic cancer who haven't responded to other treatments. The goal is to see if this combination works better than existing options. Gemcitabine has been widely used in the treatment of advanced pancreatic cancer, often in combination with other drugs to improve results.

Who Is on the Research Team?

AK

Anup Kasi, MD

Principal Investigator

University of Kansas

Are You a Good Fit for This Trial?

Adults over 18 with advanced pancreatic cancer that's unremovable or has spread, and who've had certain previous chemotherapies can join. They need a measurable tumor, good blood counts, organ function, and must use effective birth control. Exclusions include recent other cancers (except some skin/breast/cervical), heart disease, lung conditions, major surgery within the last month, or COVID-19 recently.

Inclusion Criteria

- Aspartate aminotransferase (AST), (Serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT), and (Serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × ULN OR ≤ 5 × ULN for subjects with liver metastasis
- International Normalized Ratio (INR) and/or Prothrombin Time (PT) ≤ 1.5 × ULN
My doctor agrees I can be treated with gemcitabine for my pancreatic cancer.
See 19 more

Exclusion Criteria

I have not had major surgery, except for a biopsy, in the last 4 weeks.
First degree relative of the investigator, study staff or the sponsor.
I have only been diagnosed with pancreatic cancer in the last 2 years, except for certain skin, breast, or cervical cancers treated to cure.
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Monotherapy

GP-2250 is administered as a single-dose monotherapy during Cycle 1

4 weeks
3 visits (in-person)

Combination Therapy

Participants receive GP-2250 in combination with gemcitabine in subsequent cycles

6-12 months
3 visits per 28-day cycle (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12-24 months

What Are the Treatments Tested in This Trial?

Interventions

  • GP-2250
Trial Overview The trial is testing GP-2250 combined with gemcitabine in patients who have previously been treated with fluorouracil-based chemotherapy for their pancreatic cancer. It's a phase 1 trial to see what doses are safe and how well patients tolerate this combination treatment.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: GP-2250 MonotherapyExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Geistlich Pharma AG

Lead Sponsor

Trials
45
Recruited
2,300+

Translational Drug Development

Collaborator

Trials
19
Recruited
1,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security